Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This entity is an RNA gene annotated as a "novel transcript, antisense to interleukin 3 receptor subunit alpha (IL3RA)," located on the opposite DNA strand relative to the IL3RA locus. Antisense transcripts generally have potential regulatory roles, including modulation of their sense counterpart transcripts. For protein-coding genes, antisense RNAs can influence transcription rates, nuclear processing, and RNA stability in a chromatin-dependent manner. While there is evidence that antisense transcription can modulate the dynamics of gene expression—including post-transcriptional regulation and chromatin state—the biological function and relevance of this specific antisense transcript are currently uncharacterized. There is no data supporting its role as a receptor, enzyme, transporter, or other canonical drug target. Its naming and annotation are correct, but as a target, it lacks the attributes required for established therapeutic intervention[1][5].
None established for drugs; its antisense orientation might influence IL3RA gene activity via transcriptional interference, RNA pairing, or chromatin modification
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to interleukin 3 receptor subunit alpha (ENSG00000297424).